Agilent Technologies Inc at JPMorgan Healthcare Conference Transcript
Hi. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team here at JPMorgan. I'm joined by the Agilent management team on stage as these sessions typically are, it's 40 minutes, 20 minutes of presentation and roughly 20 minutes of Q&A afterwards. (Operator Instructions) And with that, I will pass it off to Mike.
Thank you, Rachel. It's a real pleasure to be here today with all of you to share the updated story on Agilent Technologies. As we know, 2023 was quite a challenging year for the industry. But as we think about it from an asset perspective, we think these market challenges we've experienced are transitory across the industry. And as we look forward, we think Agilent is very well positioned for continued long-term growth and shareholder value creation. So why do I say that? The story I'm going to tell you today is Agilent's diversified business with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
